$ATTO
Attovia Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$22.14
▼-2.60%-$0.590
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateAttovia Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is ATTO down today? It is at $22.14 (-2.60%), and our scanner flagged it 41 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ATTO spikes, and full due diligence on ATTO — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $ATTO 41 times in the last 30 days. Create a free account to track $ATTO, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on ATTO from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ATTO today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystAttovia Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from the latest SEC filing. Read it →* Institutional ownership was unavailable, so float is insider-deduped only.
Across every filing on file, supply equal to 35.5% of the tradeable float is in play - 35.5% has already been sold.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
15,594,118 new shares · About $265.1M in size · Priced at $17/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Frazier Life Sciences Xi, L.P. Beneficial Owner (10%) | Acquired (grant/award) | +5.49M 12.0% of company | added 100% | 5.57M | n/a | Aug 6, 26 |
Frazier Life Sciences Xi, L.P. Beneficial Owner (10%) | Bought (open market) | +588K 1.3% of company | added 11% | 6.15M | $10.0M at $17.00 | Aug 6, 26 |
Sanofi Beneficial Owner (10%) | Acquired (grant/award) | +783K 1.7% of company | n/a | 783K | n/a | Aug 6, 26 |
Sanofi Beneficial Owner (10%) | Bought (open market) | +300K 0.7% of company | added 38% | 1.08M | $5.1M at $17.00 | Aug 6, 26 |
Redmile Group, Llc Beneficial Owner (10%) | Acquired (grant/award) | +783K 1.7% of company | n/a | 783K | n/a | Aug 6, 26 |
Redmile Group, Llc Beneficial Owner (10%) | Bought (open market) | +200K 0.4% of company | added 26% | 983K | $3.4M at $17.00 | Aug 6, 26 |
Redmile Group, Llc Beneficial Owner (10%) | Bought (open market) | +400K 0.9% of company | added 26% | 1.97M | $6.8M at $17.00 | Aug 6, 26 |
Venbio Global Strategic Fund Iv, L.P. Beneficial Owner (10%) | Acquired (grant/award) | +3.80M 8.3% of company | n/a | 3.80M | n/a | Aug 6, 26 |
Venbio Global Strategic Fund Iv, L.P. Beneficial Owner (10%) | Bought (open market) | +382K 0.8% of company | added 10% | 4.18M | $6.5M at $17.00 | Aug 6, 26 |
Deep Track Biotechnology Master Fund, Ltd. Beneficial Owner (10%) | Acquired (grant/award) | +1.96M 4.3% of company | n/a | 1.96M | n/a | Aug 6, 26 |
Goldman Sachs Group Inc Other | Acquired (grant/award) | +2.44M 5.3% of company | added 100% | 2.52M | n/a | Aug 6, 26 |
Goldman Sachs Group Inc Other | Bought (open market) | +500K 1.1% of company | added 9.9% | 5.54M | $8.5M at $17.00 | Aug 6, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on ATTO from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ATTO today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
ATTO last traded at $22.14, down 2.60% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
The ATTO Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ATTO 41 times in the last 30 days.
ATTO (Attovia Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $1.01B in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ATTO for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$ATTO discussion
Sign in to ask a question or join the discussion.